Phase 1RecruitingPriority 4 · Lower priorityNCT07047885
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
Plain-language summary
This trial is testing Ropeginterferon alfa-2b for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Ropeginterferon alfa-2b (DRUG): Will be administered via subcutaneous injection once every 2 weeks
Ropeginterferon alfa-2b
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details